{"filing":{"accession_number":"0001193125-26-428116","cik":"0001035354","ticker":"ELOX","company_name":"Eloxx Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-19","primary_document":"d462611d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526428116/d462611d8k.htm"},"events":[{"id":36917,"run_id":34033,"accession_number":"0001193125-26-428116","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board appointed Geno J. Germano as a new director on October 19, 2026, increasing Board size from five to six members. Germano brings extensive pharmaceutical industry experience and public company board credentials.","company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41477,"accession_number":"0001193125-26-428116","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Board's appointment of Geno J. Germano as a new director on October 19, 2026, following an increase in Board size from five to six members. While the section mentions standard indemnification and equity compensation arrangements, the principal disclosed action is the appointment of a qualified director with extensive pharmaceutical industry experience and public company board credentials. This is a material governance event affecting the composition and leadership of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:04:03.637174+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":36918,"run_id":34033,"accession_number":"0001193125-26-428116","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The Company appointed T.R. Srinivas, M.D. to the position of Senior Vice President and Chief Medical Officer, a named executive role material to the Company's clinical and regulatory strategy.","company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41478,"accession_number":"0001193125-26-428116","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the appointment of T.R. Srinivas, M.D. to Senior Vice President and Chief Medical Officer, a named executive position. While the filing also updates on the EXPRESS clinical trial design and timeline, the appointment is the primary personnel action disclosed. The CMO role is material to a biopharmaceutical company's clinical and regulatory strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:04:03.637174+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41477,"accession_number":"0001193125-26-428116","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Board's appointment of Geno J. Germano as a new director on October 19, 2026, following an increase in Board size from five to six members. While the section mentions standard indemnification and equity compensation arrangements, the principal disclosed action is the appointment of a qualified director with extensive pharmaceutical industry experience and public company board credentials. This is a material governance event affecting the composition and leadership of the Board.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:04:03.637174+00:00","company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","filing_date":"2026-10-21"},{"id":41478,"accession_number":"0001193125-26-428116","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on the appointment of T.R. Srinivas, M.D. to Senior Vice President and Chief Medical Officer, a named executive position. While the filing also updates on the EXPRESS clinical trial design and timeline, the appointment is the primary personnel action disclosed. The CMO role is material to a biopharmaceutical company's clinical and regulatory strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T10:04:03.637174+00:00","company_name":"Eloxx Pharmaceuticals, Inc.","ticker":"ELOX","filing_date":"2026-10-21"}]}